Rationale: Ventricular fibrillation (VF) leads to global ischemia. The modulation of ischemia-dependent pathways may alter the electrophysiological evolution of VF.
V entricular fibrillation (VF), once established, rarely self-terminates. The factors that tend to maintain reentry in fibrillating myocardium include increases in spatial dispersion of refractoriness and time-dependent alteration of refractory periods, which may occur in a spatially heterogeneous manner. [1] [2] [3] [4] VF leads to global ischemia and resultant activation of cardiac K ATP channels, which shorten action potential duration and refractoriness. 5 If the expression and/or function of K ATP channels is heterogeneous, VF-induced ischemic K ATP channel activation may also result in increasing spatiotemporal dispersion of refractoriness, providing conditions that are conducive for sustaining VF after its initiation. Thus, K ATP channel blockade may prevent shortening of refractoriness and cause attenuation of spatiotemporal dispersion of refracto-riness during early VF, thereby forestalling VF perpetuation. In some conditions, such as ischemic cardiomyopathy, it has been suggested that the expression of K ATP subunits is altered in infarct border zone. 6 We have previously presented preliminary data suggesting that that there is altered expression of K ATP channel subunits in human cardiomyopathic hearts compared with normal hearts. 7 It is not known if there is spatial heterogeneity and/or altered expression of K ATP channels in human cardiomyopathic hearts and if modulation of these channels in cardiomyopathic states alters the maintenance of VF.
We tested the hypotheses that (1) there is differential regional/disease-related expression of K ATP channels in human cardiomyopathic hearts, causing spatiotemporal dispersion of refractoriness, and that (2) blockade of K ATP channels by glibenclamide promotes spontaneous VF termination by attenuating this spatiotemporal dispersion.
Methods
All procedures conformed to the Helsinki Declaration of the World Medical Association. Only essential information is presented in this article in summary form. Please see the Online Data Supplement at http://circres.ahajournals.org for complete methodological details.
Human Langendorff Model
After informed consent, hearts were explanted from 15 patients with dilated cardiomyopathy who underwent cardiac transplantation and were Langendorff-perfused.
Electric Mapping
Electric mapping of the Langendorff-perfused hearts was performed with an epicardial sock covering the entire epicardial surface and a left ventricular (LV) endocardial balloon ( Figure 1B and 1C ). VF was recorded in ischemic condition for 20 seconds at the onset and after 180 seconds, in control and treatment groups (10 mol/L glibenclamide) ( Figure 1A) . We compared spontaneous defibrillation and effective refractory period (ERP) dispersion between control and treatment groups.
Spontaneous Defibrillation
The abrupt termination of VF without electric defibrillation during an episode of induced VF (lasting spontaneously Ͼ30 seconds) was considered to represent spontaneous defibrillation.
Measurement of ERP During VF
Since the traditional method of ERP measurement cannot be used at multiple sites during VF because of the dynamic nature of VF, 8 we used average local fibrillation intervals as a surrogate for ERP. 9 -14 To further validate the mechanisms found in human hearts, we studied the consequences of ischemia on Langendorff-perfused rat hearts with direct ERP and action potential measurements (see below).
Spatial Dispersion of Refractoriness
Dispersion of refractoriness was calculated between LV epicardium and endocardium (LV transmural dispersion), LV and right ventricular (RV) (interventricular dispersion), anterior and posterior LV (anterio-posterior dispersion) and apex and base (apico-basal dispersion). 
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Human Heart Samples
Human heart samples were dissected from normal and cardiomyopathic hearts for RNA and protein expression.
RNA Preparation and Quantitative PCR
RNA was isolated from endocardial and epicardial samples for quantitative PCR. ␤-Actin served as the control.
Langendorff-Perfused Rat Hearts
This protocol was approved by University Health Network Ethics Board. Male Sprague-Dawley rats were anesthetized. Hearts were rapidly isolated and Langendorff-perfused.
Electric Recording
The heart was placed on a plastic base in which 4 contact electrodes were inserted (Figure 2A ). Two electrodes were used to record LV epicardial signals and 2 were used for pacing LV epicardium. For endocardial mapping and pacing, 4 electrodes were inserted into the LV cavity, with 2 electrodes used for endocardial recording and 2 for endocardial pacing ( Figure 2B ). Figure 2C shows the experimental protocol. Hearts were paced at 150 ms (S 1 ) at twice diastolic threshold, and an extrastimulus (S 2 ) was delivered, starting from S 1 -S 2 ϭ140 ms, decreasing until capture was lost. ERP dispersion and arrhythmogenesis was measured in control group (no treatment) and after glibenclamide, pinacidil, and lidocaine.
ERP Dispersion Determination Using S 1 -S 2 Protocol
Floating Microelectrode Recording
Recordings were obtained from epicardium and endocardium under control conditions and during ischemia with and without drug treatment.
Statistical Analysis
Data were analyzed using SAS 9.0. Values are shown as meanϮSEM. The Fisher exact test and ANOVA were used, and a probability value Ͻ0.05 was considered statistically significant. Figure demonstrates a microelectrode inserted in the LV epicardium with a nearby reference touching the epicardium. The heart was allowed to rest on a plastic "chair " that had 4 contact electrodes connected to it. Two electrodes were used to record LV epicardial signals and 2 were used for pacing from LV epicardium. B, Electrodes used for endocardial ERP measurements. Two electrodes were used for pacing and 2 were used for recording capture. C, Experimental protocol used for S 1 -S 2 ERP measurements. D, Mean dispersion of refractoriness in control in control and treatment conditions. Dispersion of refractoriness (⌬ERP) was defined as the difference in refractoriness between epicardium and endocardium. Mean ⌬ERP was 5Ϯ2 ms, 36Ϯ5 ms, 0.08Ϯ3 ms, and 4.9Ϯ4 ms during baseline (without ischemia), ischemia without glibenclamide, glibenclamide with no ischemia, and glibenclamide with ischemia, respectively. Differences were statistically significant between ischemia versus baseline (without drug) and ischemia versus ischemiaϩglibenclamide (PϽ0.05). E, Action potentials, recorded using a microelectrode, from epicardium and endocardium in control condition, pinacidil, ischemia, and ischemia with glibenclamide.
Results
Spontaneous Defibrillation
Fifteen human hearts (6 control and 9 treatment) were studied. Spontaneous VF termination occurred in only 1 of 6 control hearts. In the 9 treatment hearts, spontaneous termination occurred in 2 hearts before glibenclamide administration. Figure 3A shows an example of unipolar electrograms during VF and ischemia. After treatment with glibenclamide (nϭ9), VF could not be induced in 1 heart and terminated spontaneously in 7 of the remaining 8 hearts (Pϭ0.026 versus control). Figure 3B shows an example of spontaneous termination of VF after the administration of glibenclamide.
K ATP Channel Blockade and Spatiotemporal Dispersion of Refractoriness During Fibrillation in Human Langendorff Model
Transmural Dispersion
Initially, mean VF cycle length (CL) was compared, averaging VF at onset and 180 seconds, between epicardium and endocardium in the control and glibenclamide treatment groups. Mean VFCL was 248Ϯ8 ms and 289Ϯ27 ms in control and 397Ϯ28 ms and 408Ϯ27 ms in the treatment group (PՅ0.001 versus control), in LV endocardium and epicardium, respectively. The VFCL was then compared between epicardium and endocardium in onset and early VF (180 seconds). At the onset of VF, the mean VFCL in LV endocardium and epicardium was 230Ϯ13 ms and 242Ϯ25 ms in the control group and 343Ϯ29 ms and 353Ϯ32 ms in the treatment group ( Figure 4A) . The difference between control group and the treatment group was statistically significant (Pϭ0.017), whereas the difference between epicardium and endocardium was not significant. After 180 seconds of VF, as ischemia progressed, a gradient in VFCL developed in the control group, with a mean VFCL of 279Ϯ17 ms and 337Ϯ36 ms in LV endocardium and epicardium, respectively (Pϭ0.01). In the treatment group, the difference was attenuated, with a mean VFCL of 454Ϯ34 ms and 463Ϯ27 ms, respectively, in endocardium and epicar-dium (Pϭ0.6), suggesting that K ATP channels play a key role in establishing this gradient. Figure 3C illustrates refractoriness for the LV endocardium and epicardium during the VF sequences in 1 heart.
Interventricular Dispersion
Mean VFCL was 297Ϯ29 ms and 274Ϯ22 ms in the control group and 408Ϯ28 ms and 496Ϯ24 ms in the treatment group for LV epicardium and RV epicardium, respectively. The difference was statistically significant between control and treatment (PϽ0.001) but not significant between LV and RV epicardium (Pϭ0.69). VFCL was then compared in onset and early VF (180 seconds). At the onset of VF, mean VFCL in LV and RV epicardium was 248Ϯ28 ms and 237Ϯ16 ms in control group and 353Ϯ33 ms and 363Ϯ9 ms in the treatment group. The difference between control and treatment groups was statistically significant (Pϭ0.02), whereas the difference between LV epicardium and RV epicardium was not significant (Pϭ0.9). During early VF, a small difference of 32 ms was observed between LV and RV epicardium (LV epicar-diumϭ345Ϯ37 ms, RV epicardiumϭ313Ϯ34 ms), but this failed to achieve statistical significance (Pϭ0.07). In the treatment group, the difference was attenuated, with a mean VFCL of 463Ϯ27 ms and 450Ϯ26 ms in LV and RV epicardium, respectively (Pϭ0.23).
Antero-Posterior Dispersion
At the onset of VF, the mean VFCL was 231Ϯ30 ms and 239Ϯ30 ms in the control group (Pϭ0.9) and 345Ϯ26 ms and 350Ϯ25 ms in the treatment group (Pϭ0.9) in anterior and posterior LV epicardium, respectively. During early VF (180 seconds), mean VFCL in the control group was 300Ϯ33 ms and 333Ϯ33 ms in anterior and posterior LV epicardium, respectively. The difference of 33 ms between anterior and posterior LV epicardium after 180 seconds of ischemia failed to achieve statistical significance (Pϭ0.5). After the administration of glibenclamide in the treatment group, this difference was attenuated, with a mean VFCL of 453Ϯ28 ms and 455Ϯ28 ms in the anterior and poster LV epicardium, respectively (Pϭ0.9). In the control group, CL is shorter in endocardium compared with epicardium, whereas activation rate is higher in endocardium compared with epicardium. When compared statistically, this difference in mean CL was significant between epicardium and endocardium (PϽ0.05). This difference was abolished after the administration of glibenclamide, with both epicardium and endocardium being activated at the same rate.
Apico-Basal Dispersion
Mean VFCL at the apex and the base of the heart was 258Ϯ30 ms and 287Ϯ29 ms in the control group and 373Ϯ25 ms and 423Ϯ25 ms in the treatment group, respectively. In both regions, the difference was statistically significant between control and treatment groups (PϽ0.001), but the difference between apex and base was not statistically significant (Pϭ0.15). During onset VF, the mean VFCL was 217Ϯ15 ms and 264Ϯ23 ms in the control group (Pϭ0.9) and 344Ϯ29 ms and 369Ϯ36 ms in the treatment group (Pϭ0.2) at the apex and base, respectively. During early VF (180 seconds), VFCL was 306Ϯ40 ms at the apex and 347Ϯ31 ms at the base in the control group (Pϭ0.8) and 445Ϯ36 ms at the apex and 471Ϯ25 ms at the base in the treatment group (Pϭ0.9). Though a small difference in VFCL was observed between apex and base, it was consistent in the onset, and early VF and was not affected by glibenclamide.
K ATP Channel Subunit Regional mRNA Expression in Cardiomyopathic Human Hearts
We quantified the gene expression of the 4 common subunits that make up the human cardiac K ATP channels, Kir6.1, Kir6.2, SUR1, and SUR2A, in epicardium and endocardium in 6 myopathic hearts.
K ATP Subunit Expression in LV Endocardium Versus Epicardium
K ATP subunit expression was done to evaluate if the LV transmural gradient of refractoriness was related to the differential expression of K ATP subunits in epicardium versus endocardium in cardiomyopathic hearts. All expression levels are presented relative to the housekeeping gene and normalized to LV endocardium. Mean mRNA expression levels in LV epicardium were 61Ϯ10% (Pϭ0.02), 59Ϯ13% (Pϭ0.03), 57Ϯ11% (Pϭ0.016), and 72Ϯ5% (Pϭ0.004) for Kir6.1, Kir6.2, SUR1, and SUR2A, respectively ( Figure 4B and 4C ). All subunits were less strongly expressed in LV epicardium compared with LV endocardium.
K ATP Channel Expression in LV Epicardium Versus RV Epicardium
We compared K ATP gene expression in LV epicardium and RV epicardium. Mean expression levels (relative to house- 
Langendorff-Perfused Rat Model
ERP Dispersion During K ATP Modulation
Dispersion in refractoriness (⌬ERP) was defined as the difference in the refractoriness between epicardium and endocardium ( Figure 2D ). Twenty-eight hearts were studied with a traditional S 1-S 2 protocol. Mean ⌬ERP was 5Ϯ2 ms and 36Ϯ5 ms during baseline (without ischemia) and ischemia (Pϭ0.02 versus baseline), respectively. After 10 mol/L glibenclamide (nϭ13), mean ⌬ERP was 0.1Ϯ3.0 ms and 4.9Ϯ4.0 ms during baseline (no ischemia) and ischemia with glibenclamide (Pϭ0.9 versus glibenclamide alone), respectively. Hence, glibenclamide significantly attenuated the ⌬ERP during acute ischemia (Pϭ0.019). In 7 hearts, ERP in control conditions was followed by pinacidil. Mean ⌬ERP dispersion in the presence of pinacidil was 2.7Ϯ2.0 ms in the baseline condition and 28Ϯ13 ms during acute ischemia.
There was no statistically significant difference in ⌬ERP after pinacidil, whether in the baseline condition or acute ischemia.
Arrhythmogenesis During K ATP Modulation
During control conditions, cardiac arrhythmia occurred in 15 of 28 hearts in the baseline condition and 19 of 28 hearts during acute ischemia. The difference was not statistically significant (Pϭ0.4). In 13 hearts, measurements in control conditions were followed by 10 mol/L glibenclamide. After glibenclamide, cardiac arrhythmias occurred in 10 of 13 hearts in the baseline condition (no ischemia) and 4 of 13 hearts during acute ischemia (Pϭ0.047). When compared with control, glibenclamide significantly suppressed the incidence of cardiac arrhythmias during acute ischemia (4/13 versus 19/28, Pϭ0.043). In 7 hearts, measurements during control conditions were followed by 10 mol/L pinacidil. After pinacidil, cardiac arrhythmias occurred in 5 of 7 hearts in the baseline condition (no ischemia) and 7 of 7 hearts during acute ischemia (Pϭ0.5). When compared with control, there was no difference in the incidence of cardiac arrhythmias after pinacidil during acute ischemia (Pϭ0.2).
Action Potential Changes During K ATP Modulation
To study the effect of K ATP modulation on action potential duration, membrane potentials were measured under control conditions and after K ATP modulation ( Figure 2E ). Action potential durations at 90% of repolarization (APD 90 ) were analyzed. In the baseline control condition (no ischemia, no drug), mean APD 90 was 56Ϯ3 and 55Ϯ2 ms in endocardium and epicardium, respectively (nϭ17, PϭNS). Glibenclamide did not cause any significant changes in APD in the baseline condition (nϭ7, APD 90 epicardium: 58Ϯ5 ms, endocardium: 53Ϯ3 ms; PϭNS). Pinacidil resulted in APD shortening, mainly in epicardium (nϭ5; mean APD 90 epicardium: 41Ϯ8 ms; pinacidil versus baseline; Pϭ0.049). After 3 minutes of ischemia, APD 90 was significantly shorter on epicardium compared with endocardium (epicar-dium: 55Ϯ6 ms; endocardium: 82Ϯ5 ms; Pϭ0.02). After the administration of glibenclamide, the difference in APD 90 between the epicardium and endocardium was attenuated and was not statistically significant during acute ischemia (APD 90 at 3 minutes of acute ischemia; endocardium: 83Ϯ5 ms, epicardium: 83Ϯ12 ms; PϭNS).
Lidocaine Effects on ERP and APD
In 8 hearts, control ERP dispersion measurements were followed by administration of 10 mol/L lidocaine. ERP dispersion measurements were repeated in the presence of lidocaine under baseline conditions as well as during ischemia. The mean ERP dispersion was 24Ϯ6 ms in the baseline condition (no ischemia). During ischemia, the mean ERP dispersion was 91Ϯ21 ms. The difference of dispersion between baseline and acute ischemia after lidocaine was statically significant (Pϭ0.006). When compared with control, lidocaine resulted in increased transmural gradient of ERP during ischemia (Pϭ0.02). After lidocaine, arrhythmias resulted in 50% hearts (4/8), not statistically significant from control (Pϭ0.2). Lidocaine had no significant effect on APD 90 either in epicardium or endocardium (nϭ5; mean APD 90 epicardium: 50Ϯ3 ms; endocardium: 57Ϯ2 ms). Similarly, lidocaine had no significant effect on APD in acute ischemia (eg, mean APD 90 after 3 minutes of ischemia: epicardium 43Ϯ13 ms, endocardium 70Ϯ32 ms; PϭNS versus no-drug control).
Discussion
We have demonstrated that K ATP channel blockade during VF promotes spontaneous defibrillation of cardiomyopathic human hearts by attenuating the ischemia-dependent spatiotemporal dispersion of refractoriness during early VF. The molecular basis probably involves heterogeneous and altered expression of K ATP channel subunits in cardiomyopathic hearts. After 180 seconds of VF, there is heterogeneity in refractoriness which is attenuated by blockade of K ATP channels. Taken together, our findings indicate that glibenclamide promotes spontaneous defibrillation of VF in the setting of global ischemia by the attenuation of spatiotemporal heterogeneity and increasing refractoriness during VF in cardiomyopathic hearts.
Spontaneous Defibrillation
Spontaneous defibrillation (termination of VF without highvoltage shock) is an uncommon event that has occasionally been reported in certain animal species 15 and in humans, 16 -18 but rarely in a cardiomyopathic state. The development of therapeutic strategies that would promote spontaneous defibrillation has significant clinical implications for prevention of sudden cardiac death in cardiomyopathic patients at the highest risk of VF. It is well described that shortening of the APD plays an important role in maintaining cardiac arrhythmias. 19, 20 There are various reports that glibenclamide can either prevent 21 or partially reverse 22 the APD shortening in hypoxia and ischemia 21, 22 in both isolated 22 and in situ guinea pig myocardium. 21 Our observations in the current study suggest that during VF, glibenclamide prevents APD shortening caused by acute hypoxia, ischemia, and K ATP -activation, leading to attenuation of spatiotemporal dispersion of refractoriness, thus causing spontaneous termination. A gradient in local activation rate/refractoriness existed between the LV endocardium and epicardium, probably due to differential K ATP channel gene expression. Glibenclamide, through K ATP channel blockade, resulted in a loss of this gradient. These observations suggest that spatiotemporal action potential characteristics within the LV contribute to the maintenance of VF in cardiomyopathic human hearts and are in part controlled by regionally differential consequences of K ATP activation, the effects of which are attenuated by K ATP channel blockade.
A dominant-frequency gradient has been reported during VF in various animal [23] [24] [25] and human 26 models. We hypothesized that differential function of K ATP channels might contribute to this gradient. The fact that blockade of K ATP channels by glibenclamide abolished this gradient supports this hypothesis. We further tested the hypothesis by studying the differential expression of K ATP channel subunits in LV epicardium and endocardium in cardiomyopathic hearts. The mRNA expression levels of K ATP channel subunits were significantly higher in LV endocardium compared with LV epicardium. Miyoshi et al have reported that blockade of cardiac K ATP channels by glibenclamide in dogs suppresses the extracellular K ϩ rise in epicardium, whereas the extracellular K ϩ level in endocardium remains unaffected. 27 We attribute this difference to species specific differential functioning of K ATP channels in the heart. It should also be noted that the hearts that we studied were cardiomyopathic hearts explanted from patients undergoing cardiac transplantation.
K ATP Modulation in Experimental VF
In an in vivo ischemic porcine model, the K ATP channel opener pinacidil significantly shortened the ERP from 162Ϯ16 to 130Ϯ28 ms and increased the peak frequency of the LV power spectrum during VF from 9.3Ϯ0.6 to 10.5Ϯ1.0 Hz. 28 Our data are consistent with the concept proposed regarding K ATP modulation during VF and also with the observed relation between refractory period and cycle length. Because measuring dynamic ERP changes during VF in human hearts was impossible, we used frequency indices as indicators of ERP change and conducted confirmatory experiments in an animal model to measure dispersion of refractoriness (⌬ERP) with traditional S 1 -S 2 methods. In the absence of ischemia, there was no difference in ⌬ERP between control and glibenclamide groups (5Ϯ2 versus 0.1Ϯ3.0 ms), but during ischemia there was a large, statistically significant difference (36Ϯ5 ms versus 4.9Ϯ4.0 ms). These results implicate K ATP activation and consequent increased ERP heterogeneity in ischemic conditions that could potentially serve as a substrate for sustaining VF. The fact that ventricular arrhythmias were ameliorated by glibenclamide supports this concept.
K ATP Subunit Expression
In rodent ventricular cardiomyocytes, Kir6.2/SUR2 make up the dominant K ATP channel expression. There is, however, heterogeneity within rodent hearts, with atrial cardiomyocytes expressing Kir6.2/SUR1. 29 Although the classic under-standing is that the K ATP channel in cardiomyocytes is composed mainly of Kir6.2 and SUR2A, 30 -32 more recent findings suggest that Kir6.1 and SUR1 subunits may also play significant roles. 33 Our study shows that in cardiomyopathic human left ventricles, gene expression of Kir6.1, Kir6.2, SUR1, and SUR2A is heterogeneous with greater preponderance on the endocardium. Kir6 subunit upregulation may contribute to the substantial time-dependent increases in ERP-heterogeneity during VF in cardiomyopathic hearts. Tavares et al showed similar Kir6.1-upregulation in a rodent cardiomyopathic model. 6 Hence, the relative expression of K ATP channels may be different not only in different tissues but also in different species and in different disease states. Establishing effective clinical treatments with K ATP blockade requires further evaluation of the mechanism and physiological significance of differential K ATP subunit expression/ function with heart disease. The present study provides a basis for such further work by identifying changes in K ATP subunit gene expression in cardiomyopathic human hearts.
A difference in refractoriness was observed between cardiomyopathic LV epicardium and endocardium that was attenuated by glibenclamide. In our data set, it was accompanied by increased gene expression of all K ATP subunits in LV endocardium compared with epicardium. There are other potential mechanisms of transmural K ATP function gradients in addition to transmural protein expression gradients in underlying subunits. There could be another, unidentified subunit associated with Kir6/SUR subunits that importantly modifies its function and shows differential endocardial/ epicardial expression. Alternatively, differences in myocardial energetics and oxygen demand could produce discrepant K ATP activation in LV endocardium versus epicardium. Lee et al have reported that glibenclamide inhibits Na ϩ -K ϩ pump and Ca 2ϩ channels in guinea pig hearts. 34 These effects were observed at much higher concentrations (Ն100 mol/L) than used in our study. Still, the possibility of involvement of off-target actions on other ion channels cannot be ruled out. The differential activation rate seen in our study could have another potential explanation. Conduction block of wave fronts should be considered as an explanation in addition to local refractoriness changes. Morley et al previously showed in a single-cell preparation that metabolic inhibition has a significant influence on intercellular membrane resistance and may promote conduction block. 35 However, in our rat heart study, we paced locally in a tissue preparation and were able to establish that indeed refractoriness was locally altered.
Potential Application
The only effective therapeutic strategy by which VF can be terminated once it has occurred is electric defibrillation. For a defibrillation shock to succeed, it must extinguish existing VF activations throughout a critical mass of myocardium, as well as not initiate new fibrillatory wave fronts that propagate into regions containing excitable gaps. Therefore, the present clinical strategy involves the use of implantable defibrillator devices in cardiomyopathic patients. Various chronic pharmacological strategies have been tested for the prevention or termination of VF with
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limited success, primarily due to proarrhythmic effects. 36 -40 The strategy that we tested presents the intriguing possibility of extinguishing VF activations throughout the myocardium by prolonging refractoriness and not initiating new fibrillatory wave fronts due to voltage gradients set up by high-voltage shocks. In addition, by virtue of having therapeutic electrophysiological properties mainly during ischemia, this strategy has the potential of maximal effect during the global ischemia that accompanies VF. Recently, a therapeutic strategy using spatially focalized intervention to modulate Na ϩ channel expression in the border zone of infarcted hearts has been proposed. 41 Our findings suggest a role for modulation of global ischemia-dependent pathways in a nonelectrical focal temporal defibrillation strategy by blockade of ischemia-activated K ATP channels in diseased human hearts. K ATP channel blockade may have a potential role in both the primary and secondary prevention of VF arrest. We used 10 mol/L glibenclamide, which is a higher concentration than used in reperfusion injury studies. If used clinically, this could cause hypoglycemia in normoglycemic patients. However, the use of cardioselective K ATP channel blockers such as HMR1883 [42] [43] [44] could obviate this problem in developing this treatment paradigm. In addition, cardiac K ATP channel blockers could prove to be useful adjuncts when defibrillation fails or proves difficult after cardiac surgery or for resistant VF in the cardiopulmonary resuscitation setting.
Limitations
This study was performed in a Langendorff-perfused human heart model. It is not possible with this model to study the effect of interplay of different neural and autonomic mechanisms on VF that can occur in vivo; hence, care should be maintained when extrapolating the results of this study to the clinical setting. We studied the effect of K ATP channel modulation in acute ischemia in isolated cardiomyopathic human hearts. Because the relative mRNA expression of K ATP subunits is also different in normal and cardiomyopathic hearts, the effect of modulation of K ATP channels in these scenarios needs further investigation.
It has been reported that blockade of K ATP channels might counteract ischemic preconditioning and may aggravate acute ischemic injury. The emphasis of our study was on the role of K ATP channel blockade in VF during acute ischemia, and we did not study the effect of K ATP channel modulation on ischemic injury and preconditioning. It may, however, be possible to retain an antiarrhythmic effect of K ATP channel blockade without adverse consequences for cardioprotection by selectively targeting sarcolemmal K ATP channels, which mediate action potential changes while leaving intact mitochondrial K ATP channels, which are central to preconditioning.
In our human Langendorff model, we used VFCL as a surrogate for ERP to obtain an ERP index simultaneously in multiple cardiac regions and to study the rapidly developing temporal evolution of refractoriness. Though VFCL may overestimate absolute refractoriness, previous studies suggest that there is considerable agreement be-tween pacing-based determination of refractoriness and CL in fibrillation. 45, 46 Moreover, we confirmed our principal findings with direct ERP and APD measurements in an isolated rat heart model.
In rats, transmural dispersion of ERP and APD increased with ischemia in a glibenclamide-suppressible way, as in humans; however, we observed greater ischemic ERP shortening in epicardium versus endocardium in rats, different from humans. This may be due to a species difference, because in 2 human hearts in which we were able to study monophasic action potentials during ischemia, endocardial APD decreased more than epicardial with ischemia, and the difference was attenuated with 10 mol/L glibenclamide (Online Data Supplement), fully consistent with our VFCL results.
Western blots for protein expression of K ATP channel subunits were attempted. Antibodies available for K ATP subunits were imperfect. We were unable to obtain data for SUR2A, and the staining characteristics of the available SUR1 and SUR2B antibodies were suboptimal. In addition, molecular masses of bands detected by the SUR antibodies in human tissue were different from those in heterologous systems. Finally, GAPDH signals in our SUR2B control samples were degraded, and we therefore had to use Ponceau staining as a loading control. We have provided complete original blots in the Online Data Supplement (Online Figures I through Figure IV) , and our results must be interpreted in the light of these limitations.
Conclusions
In this study, we have demonstrated that in cardiomyopathic human hearts, heterogeneous regulation of K ATP subunit gene expression is associated with increased spatiotemporal dispersion of refractoriness during VF. Glibenclamide promotes spontaneous VF termination by attenuating spatiotemporal dispersion of refractoriness that develops with ischemia as a consequence of VF. These findings suggest a role for modulation of global ischemia-dependent pathways in nonelectrical defibrillation strategies for VF.
